ROCKAWAY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial results for the third quarter ended September 30, 2026, after the market closes on Wednesday,
Submission backed by clinical data from two clinical studies representing 168 subjects demonstrating quality of life improvements and an approximately 40% reduction in neuropathic pain scores in the active treatment group ROCKAWAY, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc.
Controlled study in 50 healthy adults suggests accelerated learning, improved executive efficiency and stronger behavioral coordination. ROCKAWAY, N.J.,, Oct. 27, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine